Italian Intersociety Consensus Statement on Antithrombotic Prophylaxis in Hip and Knee Replacement and in Femoral Neck Fracture Surgery

Overview

Journal J Orthop Traumatol

Specialties Emergency Medicine
Orthopedics

Date 2011 Jan 20

PMID 21246392

Citations 11

Authors

F Randelli

F Biggi

G Della Rocca

P Grossi

D Imberti

R Landolfi

G Palareti

D Prisco

Affiliations

Soon will be listed here.

Abstract

Anticoagulant prophylaxis for preventing venous thromboembolism (VTE) is a worldwide established procedure in hip and knee replacement surgery, as well as in the treatment of femoral neck fractures (FNF). Different guidelines are available in the literature, with quite different recommendations. None of them is a multidisciplinary effort as the one presented. The Italian Society for Studies on Haemostasis and Thrombosis (SISET), the Italian Society of Orthopaedics and Traumatology (SIOT), the association of Orthopaedists and Traumatologists of Italian Hospitals (OTODI), together with the Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI) have set down easy and quick suggestions for VTE prophylaxis in hip and knee surgery as well as in FNF treatment. This inter-society consensus statement aims at simplifying the grading system reported in the literature, and its goal is to benefit its clinical application. Special focus is given to fragile patients, those with high bleeding risk, and those receiving chronic antiplatelet (APT) and vitamin K antagonists treatment. A special chapter is dedicated to regional anaesthesia and VTE prophylaxis.

Citing Articles

Hip fracture systems-European experience.

Chesser T, Inman D, Johansen A, Belluati A, Pari C, Contini A OTA Int. 2021; 3(1):e050.

PMID: 33937678 PMC: 8081469. DOI: 10.1097/OI9.0000000000000050.

Venous thromboembolism prophylaxis after hip preservation surgery: a review and presentation of institutional experience.

Rezaie A, Azboy I, Parvizi J J Hip Preserv Surg. 2018; 5(3):181-189.

PMID: 30393544 PMC: 6206688. DOI: 10.1093/jhps/hny016.

Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Vaglio S, Prisco D, Biancofiore G, Rafanelli D, Antonioli P, Lisanti M Blood Transfus. 2015; 14(1):23-65.

PMID: 26710356 PMC: 4731340. DOI: 10.2450/2015.0172-15.

Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial.

Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M ARYA Atheroscler. 2015; 10(6):292-7.

PMID: 25815018 PMC: 4354081.

Pharmacological prevention of venous thromboembolism in orthopaedic surgery.

Prisco D, Cenci C, Silvestri E, Emmi G, Ciucciarelli L Clin Cases Miner Bone Metab. 2015; 11(3):192-5.

PMID: 25568652 PMC: 4269142.

References

Horlocker T, Wedel D, Rowlingson J, Enneking F, Kopp S, Benzon H . Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010; 35(1):64-101. DOI: 10.1097/aap.0b013e3181c15c70. View

Eriksson B, Dahl O, Rosencher N, Kurth A, van Dijk C, Frostick S . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949-56. DOI: 10.1016/S0140-6736(07)61445-7. View

Eikelboom J, Quinlan D, Douketis J . Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358(9275):9-15. DOI: 10.1016/S0140-6736(00)05249-1. View

Hooker J, Lachiewicz P, Kelley S . Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. J Bone Joint Surg Am. 1999; 81(5):690-6. DOI: 10.2106/00004623-199905000-00010. View

. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006; 25(2):101-61. View

Geerts W, Bergqvist D, Pineo G, Heit J, Samama C, Lassen M . Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S-453S. DOI: 10.1378/chest.08-0656. View

Singelyn F, Verheyen C, Piovella F, Van Aken H, Rosencher N . The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg. 2007; 105(6):1540-7, table of contents. DOI: 10.1213/01.ane.0000287677.95626.60. View

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

Turpie A, Lassen M, Davidson B, Bauer K, Gent M, Kwong L . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373(9676):1673-80. DOI: 10.1016/S0140-6736(09)60734-0. View

10.

Colwell Jr C, Kwong L, Turpie A, Davidson B . Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty. 2006; 21(1):36-45. DOI: 10.1016/j.arth.2005.05.023. View

11.

Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Bandel T . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-86. DOI: 10.1056/NEJMoa076016. View

12.

Horlocker T . Low molecular weight heparin and neuraxial anesthesia. Thromb Res. 2001; 101(1):V141-54. DOI: 10.1016/s0049-3848(00)00386-8. View

13.

Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau J, Samama C . Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010; 27(12):999-1015. DOI: 10.1097/EJA.0b013e32833f6f6f. View

14.

Kakkar A, Brenner B, Dahl O, Eriksson B, Mouret P, Muntz J . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632):31-9. DOI: 10.1016/S0140-6736(08)60880-6. View

15.

Raskob G, Hirsh J . Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003; 124(6 Suppl):379S-385S. DOI: 10.1378/chest.124.6_suppl.379s. View

16.

Turpie A, Bauer K, Eriksson B, Lassen M . Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162(16):1833-40. DOI: 10.1001/archinte.162.16.1833. View

17.

Eriksson B, Dahl O, Rosencher N, Kurth A, van Dijk C, Frostick S . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5(11):2178-85. DOI: 10.1111/j.1538-7836.2007.02748.x. View

18.

Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Hornick P . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807-15. DOI: 10.1016/S0140-6736(09)62125-5. View

19.

Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Portman R . Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361(6):594-604. DOI: 10.1056/NEJMoa0810773. View

20.

Strebel N, Prins M, Agnelli G, Buller H . Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med. 2002; 162(13):1451-6. DOI: 10.1001/archinte.162.13.1451. View